A changing time

The International Society for Cellular Therapy embraces its industry members

Robert Deans, Kurt C. Gunter, Timothy Allsopp, Mark Bonyhadi, Scott R. Burger, Melissa Carpenter, Tara Clark, Charles S. Cox, Dawn Driscoll, Ed Field, Ralf Huss, René Lardenoije, Tracey A. Lodie, Chris Mason, Richard Neubiser, John E J Rasko, Jon Rowley, Richard Maziarz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profiles reported in early studies using blood-derived and adherent stem cell products, but also an inconsistent efficacy record. Further expansion has been hindered in part by a lack of capital (both private and public) and delayed entry into the cell therapy space by large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced-phase clinical trials. With recognition that the International Society for Cellular Therapy (ISCT) is uniquely positioned to serve the global translational regenerative medicine research community as a network hub for scientific standards and policy, the ISCT commissioned the establishment of an Industry Task Force (ITF) to address current and future roles for industry. The objectives of the ITF were to gather information and prioritize efforts for a new Commercialization Committee (CC) and to construct innovative platforms that would foster constructive and synergistic collaborations between industry and ISCT. Recommendations and conclusions of the ITF included that the new CC: (1) foster new relationships with therapeutic and stem cell societies, (2) foster educational workshops and forums to cross-educate and standardize practices, (3) create industry subcommittees to address priority initiatives, with clear benchmarks and global implementation, and (4) establish a framework for a greater industry community within ISCT, opening doors for industry to share the new vision for commercialization of cell therapy, emphasizing the regenerative medicine space.

Original languageEnglish (US)
Pages (from-to)853-856
Number of pages4
JournalCytotherapy
Volume12
Issue number7
DOIs
StatePublished - Nov 2010

Fingerprint

Industry
Advisory Committees
Regenerative Medicine
Therapeutics
Cell- and Tissue-Based Therapy
Stem Cells
Benchmarking
Translational Medical Research
Economics
Clinical Trials
Delivery of Health Care
Safety
Education
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Deans, R., Gunter, K. C., Allsopp, T., Bonyhadi, M., Burger, S. R., Carpenter, M., ... Maziarz, R. (2010). A changing time: The International Society for Cellular Therapy embraces its industry members. Cytotherapy, 12(7), 853-856. https://doi.org/10.3109/14653249.2010.523958

A changing time : The International Society for Cellular Therapy embraces its industry members. / Deans, Robert; Gunter, Kurt C.; Allsopp, Timothy; Bonyhadi, Mark; Burger, Scott R.; Carpenter, Melissa; Clark, Tara; Cox, Charles S.; Driscoll, Dawn; Field, Ed; Huss, Ralf; Lardenoije, René; Lodie, Tracey A.; Mason, Chris; Neubiser, Richard; Rasko, John E J; Rowley, Jon; Maziarz, Richard.

In: Cytotherapy, Vol. 12, No. 7, 11.2010, p. 853-856.

Research output: Contribution to journalArticle

Deans, R, Gunter, KC, Allsopp, T, Bonyhadi, M, Burger, SR, Carpenter, M, Clark, T, Cox, CS, Driscoll, D, Field, E, Huss, R, Lardenoije, R, Lodie, TA, Mason, C, Neubiser, R, Rasko, JEJ, Rowley, J & Maziarz, R 2010, 'A changing time: The International Society for Cellular Therapy embraces its industry members', Cytotherapy, vol. 12, no. 7, pp. 853-856. https://doi.org/10.3109/14653249.2010.523958
Deans R, Gunter KC, Allsopp T, Bonyhadi M, Burger SR, Carpenter M et al. A changing time: The International Society for Cellular Therapy embraces its industry members. Cytotherapy. 2010 Nov;12(7):853-856. https://doi.org/10.3109/14653249.2010.523958
Deans, Robert ; Gunter, Kurt C. ; Allsopp, Timothy ; Bonyhadi, Mark ; Burger, Scott R. ; Carpenter, Melissa ; Clark, Tara ; Cox, Charles S. ; Driscoll, Dawn ; Field, Ed ; Huss, Ralf ; Lardenoije, René ; Lodie, Tracey A. ; Mason, Chris ; Neubiser, Richard ; Rasko, John E J ; Rowley, Jon ; Maziarz, Richard. / A changing time : The International Society for Cellular Therapy embraces its industry members. In: Cytotherapy. 2010 ; Vol. 12, No. 7. pp. 853-856.
@article{e073e581870d46979248521ee8eb2471,
title = "A changing time: The International Society for Cellular Therapy embraces its industry members",
abstract = "The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profiles reported in early studies using blood-derived and adherent stem cell products, but also an inconsistent efficacy record. Further expansion has been hindered in part by a lack of capital (both private and public) and delayed entry into the cell therapy space by large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced-phase clinical trials. With recognition that the International Society for Cellular Therapy (ISCT) is uniquely positioned to serve the global translational regenerative medicine research community as a network hub for scientific standards and policy, the ISCT commissioned the establishment of an Industry Task Force (ITF) to address current and future roles for industry. The objectives of the ITF were to gather information and prioritize efforts for a new Commercialization Committee (CC) and to construct innovative platforms that would foster constructive and synergistic collaborations between industry and ISCT. Recommendations and conclusions of the ITF included that the new CC: (1) foster new relationships with therapeutic and stem cell societies, (2) foster educational workshops and forums to cross-educate and standardize practices, (3) create industry subcommittees to address priority initiatives, with clear benchmarks and global implementation, and (4) establish a framework for a greater industry community within ISCT, opening doors for industry to share the new vision for commercialization of cell therapy, emphasizing the regenerative medicine space.",
author = "Robert Deans and Gunter, {Kurt C.} and Timothy Allsopp and Mark Bonyhadi and Burger, {Scott R.} and Melissa Carpenter and Tara Clark and Cox, {Charles S.} and Dawn Driscoll and Ed Field and Ralf Huss and Ren{\'e} Lardenoije and Lodie, {Tracey A.} and Chris Mason and Richard Neubiser and Rasko, {John E J} and Jon Rowley and Richard Maziarz",
year = "2010",
month = "11",
doi = "10.3109/14653249.2010.523958",
language = "English (US)",
volume = "12",
pages = "853--856",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - A changing time

T2 - The International Society for Cellular Therapy embraces its industry members

AU - Deans, Robert

AU - Gunter, Kurt C.

AU - Allsopp, Timothy

AU - Bonyhadi, Mark

AU - Burger, Scott R.

AU - Carpenter, Melissa

AU - Clark, Tara

AU - Cox, Charles S.

AU - Driscoll, Dawn

AU - Field, Ed

AU - Huss, Ralf

AU - Lardenoije, René

AU - Lodie, Tracey A.

AU - Mason, Chris

AU - Neubiser, Richard

AU - Rasko, John E J

AU - Rowley, Jon

AU - Maziarz, Richard

PY - 2010/11

Y1 - 2010/11

N2 - The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profiles reported in early studies using blood-derived and adherent stem cell products, but also an inconsistent efficacy record. Further expansion has been hindered in part by a lack of capital (both private and public) and delayed entry into the cell therapy space by large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced-phase clinical trials. With recognition that the International Society for Cellular Therapy (ISCT) is uniquely positioned to serve the global translational regenerative medicine research community as a network hub for scientific standards and policy, the ISCT commissioned the establishment of an Industry Task Force (ITF) to address current and future roles for industry. The objectives of the ITF were to gather information and prioritize efforts for a new Commercialization Committee (CC) and to construct innovative platforms that would foster constructive and synergistic collaborations between industry and ISCT. Recommendations and conclusions of the ITF included that the new CC: (1) foster new relationships with therapeutic and stem cell societies, (2) foster educational workshops and forums to cross-educate and standardize practices, (3) create industry subcommittees to address priority initiatives, with clear benchmarks and global implementation, and (4) establish a framework for a greater industry community within ISCT, opening doors for industry to share the new vision for commercialization of cell therapy, emphasizing the regenerative medicine space.

AB - The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profiles reported in early studies using blood-derived and adherent stem cell products, but also an inconsistent efficacy record. Further expansion has been hindered in part by a lack of capital (both private and public) and delayed entry into the cell therapy space by large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced-phase clinical trials. With recognition that the International Society for Cellular Therapy (ISCT) is uniquely positioned to serve the global translational regenerative medicine research community as a network hub for scientific standards and policy, the ISCT commissioned the establishment of an Industry Task Force (ITF) to address current and future roles for industry. The objectives of the ITF were to gather information and prioritize efforts for a new Commercialization Committee (CC) and to construct innovative platforms that would foster constructive and synergistic collaborations between industry and ISCT. Recommendations and conclusions of the ITF included that the new CC: (1) foster new relationships with therapeutic and stem cell societies, (2) foster educational workshops and forums to cross-educate and standardize practices, (3) create industry subcommittees to address priority initiatives, with clear benchmarks and global implementation, and (4) establish a framework for a greater industry community within ISCT, opening doors for industry to share the new vision for commercialization of cell therapy, emphasizing the regenerative medicine space.

UR - http://www.scopus.com/inward/record.url?scp=77958008936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958008936&partnerID=8YFLogxK

U2 - 10.3109/14653249.2010.523958

DO - 10.3109/14653249.2010.523958

M3 - Article

VL - 12

SP - 853

EP - 856

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 7

ER -